Abstract
The SARS-CoV-2 pandemic and the vaccination effort that is ongoing has created an unmet need for accessible, affordable, flexible and precise platforms for monitoring the induction, specificity and maintenance of virus-specific immune responses. Herein we validate a multiplex (Luminex-based) assay capable of detecting SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type (e.g. plasma, serum, saliva or blood spots). The well-established precision of Luminex-based assays provides the ability to follow changes in antibody levels over time to many antigens, including multiple permutations of the most common SARS-CoV-2 antigens. This platform can easily measure antibodies known to correlate with neutralization activity as well as multiple non-SARS-CoV-2 antigens such as vaccines (e.g. Tetanus toxoid) or those from frequently encountered agents (influenza), which serve as stable reference points for quantifying the changing SARS-specific responses. All of the antigens utilized in our study can be made in-house, many in E. coli using readily available plasmids. Commercially sourced antigens may also be incorporated and newly available antigen variants can be rapidly produced and integrated, making the platform adaptable to the evolving viral strains in this pandemic.
Brief Summary A multi-antigen assay for monitoring SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type was developed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for this work was provided by grant R01AI125738 to RLT from the National Institutes of Health and a University of Georgia Athletic Association endowment to RLT. S.M.T. and T.M.R. are partially supported by NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400004C and from the University of Georgia. T.M.R and LW are also supported, in part, by the Georgia Research Alliance as an Eminent Scholar and a Distinguished Investigator, respectively. Additional support for specimen collection and processing of samples in cohort 2 was provided by the Georgia Emerging Infections Program, which was funded through the Centers for Disease Control and Prevention Emerging Infections Program [U50CK000485]. Pet dog and cat samples were collected with funding from the Centers for Disease Control and Prevention RFP 75D 301-20-R-68167.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sample collection at the University of Georgia (cohort 1) was reviewed and approved by the University of Georgia Institutional Review Board (Protocol # 20202906) and at Emory University was performed under two protocols, which were reviewed by the Emory University Institutional Review Board: IRB#00000505 (cohort 2) and IRB#00022371 (cohort 3). All pet samples were obtained from privately-owned animals in adherence with animal use protocols approved by the Texas A&M University's Institutional Animal Care and Use Committee (IACUC) and Clinical Research Review Committee (CRRC) on May 14, 2020 (2018-0460 CA). Written consent was received for each pet from the owner.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors have declared that no conflicts of interest exists.
Data Availability
All data generated or analysed during this study are included in this published article (and its supplementary information files).
